Log in

Relevant bibliographies by topics / Iron Therapeutic use Tanzania

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Iron Therapeutic use Tanzania'

Author: Grafiati

Published: 4 June 2021

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Iron Therapeutic use Tanzania.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Iron Therapeutic use Tanzania"

1

Hatcher, Heather C., Ravi N. Singh, Frank M. Torti, and Suzy V. Torti. "Synthetic and natural iron chelators: therapeutic potential and clinical use." Future Medicinal Chemistry 1, no. 9 (December 2009): 1643–70. http://dx.doi.org/10.4155/fmc.09.121.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Bhandari, Bharti, and Anita Mehta. "Serum iron and serum retinol level of severe acute malnourished children on therapeutic intervention with WHO/UNICEF recommended therapeutic food and home based therapeutic food." International Journal of Contemporary Pediatrics 8, no. 2 (January 22, 2021): 337. http://dx.doi.org/10.18203/2349-3291.ijcp20210125.

Full text

Abstract:

Background: The prevalence of anaemia and vitamin A deficiency among children with severe acute malnutrition (SAM) and their correction during nutritional rehabilitation are not well documented. This study assessed serum iron and serum retinol levels, effect of ready-to-use therapeutic foods (RUTF) and home based treatment on levels of serum iron and serum retinol level in SAM children.Methods: This was a simple randomised controlled trial in 6-59 months old children with SAM. Two groups of 70 each were divided, one was given RUTF and other home based food comparable to RUTF. Serum retinol and serum iron were measured on day 1 and 6 weeks of therapy.Results: Home based food was found better in terms of increase in serum iron than RUTF while there was no difference in rise of serum retinol in both the groups. There was no significant difference between day 1 value of serum iron in both the groups as p value was 0.82 but the level of serum iron at 6 weeks has shown significant difference in both the groups as p value was 0.0014 so there was significant increase in serum iron in group B in comparison to group A; the serum retinol value in both the groups has not shown any significant improvement.Conclusions: It was concluded home based food is better in correcting iron deficiency in SAM children as it is cheap, easily available, palatable, and acceptable than RUTF.

APA, Harvard, Vancouver, ISO, and other styles

3

Boshuizen, M., K. van der Ploeg, L. von Bonsdorff, B. J. Biemond, S. S. Zeerleder, R. van Bruggen, and N. P. Juffermans. "Therapeutic use of transferrin to modulate anemia and conditions of iron toxicity." Blood Reviews 31, no. 6 (November 2017): 400–405. http://dx.doi.org/10.1016/j.blre.2017.07.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Makis, Alexandros, Ersi Voskaridou, Ioannis Papassotiriou, and Eleftheria Hatzimichael. "Novel Therapeutic Advances in β-Thalassemia." Biology 10, no. 6 (June 18, 2021): 546. http://dx.doi.org/10.3390/biology10060546.

Full text

Abstract:

The main characteristic of the pathophysiology of β-thalassemia is reduced β-globin chain production. The inevitable imbalance in the α/β-globin ratio and α-globin accumulation lead to oxidative stress in the erythroid lineage, apoptosis, and ineffective erythropoiesis. The result is compensatory hematopoietic expansion and impaired hepcidin production that causes increased intestinal iron absorption and progressive iron overload. Chronic hemolysis and red blood cell transfusions also contribute to iron tissue deposition. A better understanding of the underlying mechanisms led to the detection of new curative or “disease-modifying” therapeutic options. Substantial evolvement has been made in allogeneic hematopoietic stem cell transplantation with current clinical trials investigating new condition regimens as well as different donors and stem cell source options. Gene therapy has also moved forward, and phase 2 clinical trials with the use of β-globin insertion techniques have recently been successfully completed leading to approval for use in transfusion-dependent patients. Genetic and epigenetic manipulation of the γ- or β-globin gene have entered the clinical trial setting. Agents such as TGF-β ligand traps and pyruvate kinase activators, which reduce the ineffective erythropoiesis, have been tested in clinical trials with favorable results. One TGF-β ligand trap, luspatercept, has been approved for use in adults with transfusion-dependent β-thalassemia. The induction of HbF with the phosphodiesterase 9 inhibitor IMR-687, which increase cyclic guanosine monophosphate, is currently being tested. Another therapeutic approach is to target the dysregulation of iron homeostasis, using, for example, hepcidin agonists (inhibitors of TMPRSS6 and minihepcidins) or ferroportin inhibitors (VIT-2763). This review provides an update on the novel therapeutic options that are presently in development at the clinical level in β-thalassemia.

APA, Harvard, Vancouver, ISO, and other styles

5

Islam, Sufia, Nazia Hoque, Nishat Nasrin, Mehnaz Hossain, Farhana Rizwan, Kushal Biswas, Muhammad Asaduzzaman, et al. "Iron Overload and Breast Cancer: Iron Chelation as a Potential Therapeutic Approach." Life 12, no. 7 (June 27, 2022): 963. http://dx.doi.org/10.3390/life12070963.

Full text

Abstract:

Breast cancer has historically been one of the leading causes of death for women worldwide. As of 2020, breast cancer was reported to have overtaken lung cancer as the most common type of cancer globally, representing an estimated 11.3% of all cancer diagnoses. A multidisciplinary approach is taken for the diagnosis and treatment of breast cancer that includes conventional and targeted treatments. However, current therapeutic approaches to treating breast cancer have limitations, necessitating the search for new treatment options. Cancer cells require adequate iron for their continuous and rapid proliferation. Excess iron saturates the iron-binding capacity of transferrin, resulting in non-transferrin-bound iron (NTBI) that can catalyze free-radical reactions and may lead to oxidant-mediated breast carcinogenesis. Moreover, excess iron and the disruption of iron metabolism by local estrogen in the breast leads to the generation of reactive oxygen species (ROS). Therefore, iron concentration reduction using an iron chelator can be a novel therapeutic strategy for countering breast cancer development and progression. This review focuses on the use of iron chelators to deplete iron levels in tumor cells, specifically in the breast, thereby preventing the generation of free radicals. The inhibition of DNA synthesis and promotion of cancer cell apoptosis are the targets of breast cancer treatment, which can be achieved by restricting the iron environment in the body. We hypothesize that the usage of iron chelators has the therapeutic potential to control intracellular iron levels and inhibit the breast tumor growth. In clinical settings, iron chelators can be used to reduce cancer cell growth and thus reduce the morbidity and mortality in breast cancer patients.

APA, Harvard, Vancouver, ISO, and other styles

6

Casu, Carla, and Stefano Rivella. "Iron age: novel targets for iron overload." Hematology 2014, no. 1 (December 5, 2014): 216–21. http://dx.doi.org/10.1182/asheducation-2014.1.216.

Full text

Abstract:

Abstract Excess iron deposition in vital organs is the main cause of morbidity and mortality in patients affected by β-thalassemia and hereditary hemochromatosis. In both disorders, inappropriately low levels of the liver hormone hepcidin are responsible for the increased iron absorption, leading to toxic iron accumulation in many organs. Several studies have shown that targeting iron absorption could be beneficial in reducing or preventing iron overload in these 2 disorders, with promising preclinical data. New approaches target Tmprss6, the main suppressor of hepcidin expression, or use minihepcidins, small peptide hepcidin agonists. Additional strategies in β-thalassemia are showing beneficial effects in ameliorating ineffective erythropoiesis and anemia. Due to the suppressive nature of the erythropoiesis on hepcidin expression, these approaches are also showing beneficial effects on iron metabolism. The goal of this review is to discuss the major factors controlling iron metabolism and erythropoiesis and to discuss potential novel therapeutic approaches to reduce or prevent iron overload in these 2 disorders and ameliorate anemia in β-thalassemia.

APA, Harvard, Vancouver, ISO, and other styles

7

Sohn, Yang-Sung, William Breuer, Arnold Munnich, and Z. Ioav Cabantchik. "Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications." Blood 111, no. 3 (February 1, 2008): 1690–99. http://dx.doi.org/10.1182/blood-2007-07-102335.

Full text

Abstract:

AbstractVarious pathologies are characterized by the accumulation of toxic iron in cell compartments. In anemia of chronic disease, iron is withheld by macrophages, leaving extracellular fluids iron-depleted. In Friedreich ataxia, iron levels rise in the mitochondria of excitable cells but decrease in the cytosol. We explored the possibility of using deferiprone, a membrane-permeant iron chelator in clinical use, to capture labile iron accumulated in specific organelles of cardiomyocytes and macrophages and convey it to other locations for physiologic reuse. Deferiprone's capacity for shuttling iron between cellular organelles was assessed with organelle-targeted fluorescent iron sensors in conjunction with time-lapse fluorescence microscopy imaging. Deferiprone facilitated transfer of iron from extracellular media into nuclei and mitochondria, from nuclei to mitochondria, from endosomes to nuclei, and from intracellular compartments to extracellular apotransferrin. Furthermore, it mobilized iron from iron-loaded cells and donated it to preerythroid cells for hemoglobin synthesis, both in the presence and in the absence of transferrin. These unique properties of deferiprone underlie mechanistically its capacity to alleviate iron accumulation in dentate nuclei of Friedreich ataxia patients and to donate tissue-chelated iron to plasma transferrin in thalassemia intermedia patients. Deferiprone's shuttling properties could be exploited clinically for treating diseases involving regional iron accumulation.

APA, Harvard, Vancouver, ISO, and other styles

8

Torshin, I. Yu, and O. A. Gromova. "Worldwide experience of the therapeutic use of the human placental hydrolytes." Experimental and Clinical Gastroenterology 1, no. 10 (March 2, 2020): 79–89. http://dx.doi.org/10.31146/1682-8658-ecg-170-10-79-89.

Full text

Abstract:

Here we present the results of a systematic analysis of publications on the clinical and the experimental pharmacology of human placental hydrolyzates (HPH). Searches were performed in the PUBMED, ELIBRARY and RSL databases. The results of the analyses of the peptide composition of HPH allowed us to formulate a number of previously unknown molecular mechanisms of their action. In the article we examine the effects of HPH in the therapy of liver diseases, atopic dermatitis, herpetic infection, viral hepatitis, joint diseases, iron overload, chronic fatigue syndrome and consider the general regenerative abilities of the HPH.

APA, Harvard, Vancouver, ISO, and other styles

9

Scott, Cassidy, Gaurav Arora, Kayle Dickson, and Christian Lehmann. "Iron Chelation in Local Infection." Molecules 26, no. 1 (January 2, 2021): 189. http://dx.doi.org/10.3390/molecules26010189.

Full text

Abstract:

Iron is an essential element in multiple biochemical pathways in humans and pathogens. As part of the innate immune response in local infection, iron availability is restricted locally in order to reduce overproduction of reactive oxygen species by the host and to attenuate bacterial growth. This physiological regulation represents the rationale for the therapeutic use of iron chelators to support induced iron deprivation and to treat infections. In this review paper we discuss the importance of iron regulation through examples of local infection and the potential of iron chelation in treating infection.

APA, Harvard, Vancouver, ISO, and other styles

10

Moscheo, Carla, Elisa Fenizia, Mariaclaudia Meli, and Giovanna Russo. "Anemia sideropenica in età pediatrica: pillole di… ferro." QUADERNI ACP 28, no. 4 (2021): 173. http://dx.doi.org/10.53141/qacp.2021.176-180.

Full text

Abstract:

Iron deficiency anemia is the most frequent haematological disorder in children. Although much is already known about the diagnostic-therapeutic approach, new frontiers regarding its diagnosis and therapeutic options emerge every day. An adequate intake with the diet is essential and can also be obtained in compliance with vegetarian-type diets. The use of glycinate or lysosomal preparations could positively affect the efficacy of therapy reducing the side effects associated with commonly used iron preparations. Parenteral iron therapy in pediatric age, which is currently limited to selected conditions, may evolve further, as a consequence of the production of molecules such as ferrocarboxymaltose, the use of which is not currently permitted under the age of 14. Further studies are therefore necessary in order to implement the knowledge and diagnostic-therapeutic interventions related to this widespread nosological entity.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Iron Therapeutic use Tanzania"

1

Mwanri, Lillian. "Impact of vitamin A and iron on anaemia and cognitive functioning of anaemic school children in Tanzania." Title page, table of contents and summary only, 2001. http://web4.library.adelaide.edu.au/theses/09PH/09phm994.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Mouralian, Cindy. "Evaluation of novel iron chelators for therapeutic use in secondary iron overload disorders." Thesis, McGill University, 2000. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=33071.

Full text

Abstract:

Pyridoxal isonicotinoyl hydrazone (PIH) has been described as an orally effective Fe chelator. It is both membrane permeable and plasma soluble, and has a high affinity for Fe, making it an ideal model on which to base future chelators. Ten novel ligands have been synthesized based on these attributes. Characterization experiments were performed to determine the ligands' selectivity and binding affinity for iron, their lipophilicity as both free and Fe-ligand complexes, and their stoichiometric relationship with iron. Efficacy of the chelators has been determined through their ability to effectively mobilize non-heme 59Fe from pre-labeled cells. Intracellular levels of chelator bound 59Fe were also determined. Concentration-dependence and time-dependence mobilization experiments were performed to determine the minimal concentrations of ligands required to elicit maximal 59Fe release. Toxicity experiments with various ligand concentrations were performed in order to determine the concentration which inhibits at least half of cellular growth as compared with control. (Abstract shortened by UMI.)

APA, Harvard, Vancouver, ISO, and other styles

3

Li, Niya, and 李妮婭. "Meta-analysis of the safety of iron chelating agents." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/208520.

Full text

Abstract:

Background: Thalassaemia is a genetic disorder disease, one of the most clinically relevant haemoglobinopathies in paediatric population. It interferes with the synthesis of haemoglobin chain. For the sake of maintaining the serum haemoglobin at a normal level, regular blood cell transfusion is required to the patients with thalassaemia. In general, patients with thalassaemia are often diagnosed at an early age and need to take a life-long iron chelating therapy to prevent the multi-organ failure caused by iron-overload. The safety issue is considered a very importance aspect in the treatment among paediatric population and young people. In the past decades, numerous randomised controlled trials (RCTs) and meta-analysis regarding the efficacy and safety of iron chelating agents including deferoxamine, deferiprone, deferasirox, in reducing iron accumulation among patients with thalassaemia had been published, yet limited meta-analysis reveal the same issue among paediatric population and young adults. Further evidence and understanding are therefore needed to confirm whether or not the iron chelating agents are safe among young patients with thalassaemia. Objective: To conduct a meta-analysis to evaluate the safety of iron chelating agents in paediatric population and young adults with thalassaemia. Methods: Literature search was carried out in PubMed, EMBASE, BIOSIS Previews, Science Citation Index Expanded and Cochrane Library databases. This meta-analysis of observational studies was conducted following the PRISMA and MOOSE statements. Selection Criteria All prospective uncontrolled cohort studies were eligible to include. Articles were assessed according to the age range of its participants and the quality of the reported adverse effects. All enrolled studies should record countable cases of adverse effects of paediatric population and young patients up to 25 years of age, diagnosed with alpha/beta thalassaemia or sickle cell disease and under the treatment of iron chelating agents. Data Collection and analysis Two reviewers independently retrieved the data and conducted the quality assessment for each of the included studies. Agency for healthcare research and quality assessment tool was used to evaluate the general risk of bias, whilst the quality of harms was assessed with the Mcharm question criterions. Meta-analysis was carried out for detecting the entire proportion value of six adverse effects including liver abnormality, renal abnormality, rash, abdominal pain/discomfort, nausea and neutropenia, and the forest plot was generated accordingly. The I2 was estimated to assess the methodological quality of each outcome. Random or fixed model was used for the analysis. The sensitivity analysis was conducted to assess the robust of the result. Results A total of 8199 articles were identified in the initial database search. After removal of duplications, update from other sources and exclusion based on the exclusion criteria, 25 full articles were retrieved and 14 uncontrolled cohort studies were included in this review. Eight hundred and fifty-four patients up to 25 years of age were included in the analysis. The general quality of the studies was moderate while the quality of adverse effects was low to moderate. Out of the 14 included studies, nine were under the deferasirox treatment; five for deferiprone therapy. No study included deferoxamine. Most adverse effects were observed among the paediatric patients under deferasirox treatment. The meta-analysis of pooled proportion under deferasirox were 17.23% (95%CI, 8.78-25.68%) for liver abnormality, 11.58% (95%CI, 5.91-17.25%) for renal abnormality, 5.41% (95%CI, 3.23-7.58%) for rash, 11.03% (95%CI, 1.83-20.22%) for abdominal pain/discomfort and 5.77% (95%CI, 1,50-10.03%) for nausea. Only one study reported case of neutropenia in the patients under deferasirox, whereas more cases were recorded within the paediatric patients with deferiprone, estimated proportion of 5.98% (95%CI, 2.79-9.16%). However, the meta-analysis of estimated proportion for liver abnormality in paediatric patients with deferiprone was 10.08% (95%CI, 2.67-17.49%), abdominal pain/discomfort was 4.31% (95%CI, 1.65-6.98%). Only one study reported case of renal abnormality, rash and nausea respectively in the patients with deferasirox, which a meta-analysis could not be conducted. Conclusions Among paediatric population and young patients with thalassaemia disease, most drug-related adverse effects were liver injury among patients under both deferasirox and deferiprone. For patients under deferasirox, the proportions of the risk of abdominal pain/discomfort and renal abnormality were in a secondary high-level, whereas the proportions of the risk of rash and nausea were comparatively very low. Few adverse effects were detected among young patients with deferiprone. In addition, the proportion of liver abnormality and abdominal pain/discomfort were lower for deferiprone than deferasirox. Further investigation is needed to assess the safety and efficacy between different dosage of iron chelating agents and the risk of other adverse effects among paediatric population, which are necessary to guide the clinical practice in the treatment of paediatric patients with thalassaemia.
published_or_final_version
Pharmacology and Pharmacy
Master
Master of Medical Sciences

APA, Harvard, Vancouver, ISO, and other styles

4

Sarmento, Carlos V. 1980. "Assessment of new iron chelating agents for treatment of iron-overload." Thesis, McGill University, 2007. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=116063.

Full text

Abstract:

Patients with acquired iron overload require chelation therapy using either Desferal or Exjade. Iron in excess may promote free radical formation in the Fenton reaction resulting in severe injuries of heart, liver and endocrine organs. Che1ators that bind ferric iron (Fe+3) in a 1:1 complex (Desferal) sequester it more efficiently than those che1ators that form 2:1 (Exjade) complexes. We initiated synthesis of new chelators derived from the tridentate chelator pyridoxal isonicotinoyl hydrazone (PIH) and its analogs. The aim of the synthesis was to generate chelators that bind iron in a 1:1 complex, which was confirmed for 8LK02, 10LK02, 11LK02 and 15LK03 by spectrophotometry. All novel chelators mobilized iron more efficiently compared to Desferal and Exjade from murine reticulocytes and human myeloid leukemia cells (K562). Additionally, aforementioned four chelators were also more efficient than PIH and were found to be less or equally toxic as Desferal and Exjade.

APA, Harvard, Vancouver, ISO, and other styles

5

Wong, Lai-Ming Ella, and 黃禮明. "Iron and ruthenium complexes with nitrogen and oxygen donor ligands for anti-cancer and anti-viral studies." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2006. http://hub.hku.hk/bib/B3587742X.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mwanri, Lillian. "Impact of vitamin A and iron on anaemia and cognitive functioning of anaemic school children in Tanzania / Lillian Mwanri." Thesis, 2001. http://hdl.handle.net/2440/21747.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Mukaya, Hembe Elie. "Macromolecular antineoplastic iron and platinum co-ordination compounds." Thesis, 2014.

Find full text

Abstract:

A thesis submitted to the Faculty of Science, University of the Witwatersrand, Johannesburg, in fulfillment of the requirements for the degree of Doctor of Philosophy of Science. Johannesburg, 2013
Chemotherapy, while representing a vital component of cancer treatment modalities, has so far not fulfilled basic expectations with unsatisfactory cure rates and frequent relapse due to limited effectiveness of the therapeutic drugs, severe side effects and resistance problems. The platinumcontaining drugs used in present clinical practice are no exception to this generalized finding. While highly effective against a small number of malignancies, they generally share in the deficiencies of other anticancer agents. To address this issue, intense research is being undertaken to develop novel platinum-compounds offering enhanced therapeutic effectiveness. To accomplish this, several new avenues of development are being pursued world-wide, and one of these involving the binding of monomeric anticancer drug systems to water-soluble, biocompatible and biodegradable polymeric carriers, was utilized in the current research. As part of the ongoing research, this dissertation demonstrates the preparation of several water-soluble polymeric carriers bearing pre-synthesized monomers aimed to anchor the platinum drug. The monomers of interest were aspartic acid, p-aminobenzoic acid and p-aminosalicylic acid derivatives; while the water-soluble carriers were polyaspartamides, prepared by an aminolytic ring-opening process of polysuccinimide. The platination agents were conjugated to the polymer backbone both via amine and via leaving-group ligands, such as dihydroxylato, dicarboxylato and carboxylatohydroxylato. In order to demonstrate the multidrug-binding capacity of the carriers, platinum complexes were co-conjugated to polymeric conjugates containing ferrocene. The in vitro studies against a human breast cancer (MCF-7) cell line showed IC50 values ranging from 48.92 μg.mL-1 to 281.37 μg.mL-1 for the platinum conjugates, 13.18 μg.mL-1 to 149.67 μg.mL-1 for ferrocene conjugates and 6.22 μg.mL-1 to 83.86 μg.mL-1 for platinum/ferrocene co-conjugates; and these values were on average 4 fold more active than the parent drug. The results of these preliminary tests provide proof of the principle that polymer-drug conjugates can play a role in future cancer therapy.

APA, Harvard, Vancouver, ISO, and other styles

8

Lee, Chia-Lin. "Vitamin E and iron status in hemodialysis patients." Thesis, 2002. http://hdl.handle.net/1957/27225.

Full text

Abstract:

The present study investigated whether vitamin E supplementation reduced oxidative stress in erythrocytes and improved vitamin E status in patients undergoing hemodialysis (HD). Plasma and erythrocyte α-tocopherol, plasma ascorbic acid, and iron status were determined in 11 regular HD patients prior to and post-dialysis, before and during oral supplementation of vitamin E, 400 IU daily for two months. HD patients were categorized into two groups according to their plasma ascorbic acid levels. We found that only the vitamin C sufficient group (>40 μM, Group I) had reliable measurements of erythrocyte α-tocopherol concentrations before vitamin E supplementation. In Group I prior to dialysis, erythrocyte α-tocopherol concentrations increased in response to vitamin E supplementation from 6.7 ± 0.7 μmol/L packed cells to 9.8 ± 0.6 (μmol/L packed cells (p<0.04). Moreover, there was a positive correlation (pGraduation date: 2003

APA, Harvard, Vancouver, ISO, and other styles

9

Schwendenwein, Shayne. "Idle Iron: Adaptive re-use of oil rigs into reef rehabilitation machines that decompose to form coral reef - Mtwara, Tanzania." Thesis, 2013. http://hdl.handle.net/10539/13095.

Full text

Abstract:

I want to design a prototype where retired oil rigs of various types can be towed to nearby reef biodiversity areas under threat, converted into reef rehabilitators and researchers, community educators, and tourism friendly machines that will biodegrade over time to form artificial reefs. The premise is to get the communities reliant on the reef to get involved by teaching sustainable fishing methods, showing that tourism is a sustainable and growing income, spreading the word via radio and education and thus stemming the damage on reefs. During the reef’s life-span as a machine, certain parts will become obsolete, functions will be upgraded or found redundant, and these will be detached and sunk as artificial reef substrate, so the reef sinks over time, becoming more and more reef, and less and less rig. This continues until a point where the rig has served its purpose, is no longer functional and becomes another wreck off the shore of mtwara slowly biodegrading into a living reef. This prototype will be adapted and become site specific, which is where the Mtwara area will be significant. Program will be informed by the prototype, but adapted to suit climate and local requirement. Materials will also be site specific according to local practice and availability, but according to the prototype, will be of a bio-degradable nature, chosen for their rates of decomposition and will all be primarily chosen because they are good reef substrate. This in essence generates a plan, rather than a building - it becomes a process that the locals can see unfold and get involved in, and translates into a machine rather than a stagnant piece of architecture.

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Iron Therapeutic use Tanzania"

1

Irving, Holly Berry. Iron and human nutrition: Research & reference materials, 1982-1986 : 176 citations. Beltsville, Md: U.S. Dept. of Agriculture, National Agricultural Library, 1987.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Irving, Holly Berry. Iron and human nutrition: Research and reference materials, 1983-1987 : 138 citations. Beltsville, Md: U.S. Dept. of Agriculture, National Agricultural Library, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Mizner, Gail Elizabeth. The effects of desferrioxamine iron chelation therapy in hypertransfused beta-thalassemia patients. [New Haven: s.n.], 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Kim, Chong-ju. B-pyŏngdong sihwajŏn: Si chʻiryo ŭi iron kwa silche : kotʻong ŭi yuksŏng. Sŏul-si: Hana Ŭihaksa, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

1945-, Bergeron Raymond J., and Brittenham Gary M, eds. The Development of iron chelators for clinical use. Boca Raton: CRC Press, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Kŏn'gang yaksŏn chori: Iron mit silsŭp = Health food based on Oriental medicinal theory. Kyŏnggi-do P'aju-si: Chigu Munhwasa, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Christos, Kattamis, ed. Iron overload and chelation in thalassaemia: A symposium held during the 2nd International Conference on Thalass[a]emia and the Hemoglobinopathies, Herakleion, Crete, 1987. Toronto: H. Huber Publishers, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Workshop for Reviewing the Salt Regulations (2003 Kibaha, Tanzania). Prevention and control of iodine deficiency disorders in Tanzania: Proceedings of the Workshop for Reviewing the Salt Regulations : held at Njuweni Hotel, Kibaha, 5th-7th February 2003. [Dar es Salaam]: NCCIDD, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

R, Tatala S., Shirika la Chakula Bora Tanzania., and Chalmers tekniska hogskola. Dept. of Food Science., eds. Prevalence of iron deficiency anaemia in preschool children and the effect of vitamin C supplementation: A study carried out in Msoga Village, Coast Region, Tanzania, 1992/1993. Dar es Salaam, Tanzania: Tanzania Food and Nutrition Centre, 1993.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

(Editor), David G. Badman, Raymond J. Bergeron (Editor), and Gary M. Brittenham (Editor), eds. Iron Chelators: New Development Strategies. Saratoga Group, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Iron Therapeutic use Tanzania"

1

Templeton, D. M. "Therapeutic Use of Chelating Agents in Iron Overload." In Toxicology of Metals, 305–31. Berlin, Heidelberg: Springer Berlin Heidelberg, 1995. http://dx.doi.org/10.1007/978-3-642-79162-8_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

"3. IRON CHELATION FOR IRON OVERLOAD IN THALASSEMIA." In Essential Metals in Medicine: Therapeutic Use and Toxicity of Metal Ions in the Clinic, 49–86. De Gruyter, 2019. http://dx.doi.org/10.1515/9783110527872-003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

"5. INFECTIONS ASSOCIATED WITH IRON ADMINISTRATION." In Essential Metals in Medicine: Therapeutic Use and Toxicity of Metal Ions in the Clinic, 123–56. De Gruyter, 2019. http://dx.doi.org/10.1515/9783110527872-005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

"6. IRON OXIDE NANOPARTICLE FORMULATIONS FOR SUPPLEMENTATION." In Essential Metals in Medicine: Therapeutic Use and Toxicity of Metal Ions in the Clinic, 157–80. De Gruyter, 2019. http://dx.doi.org/10.1515/9783110527872-006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Farag, Mayada R., Mahmoud Alagawany, Mohamed E. Abd El-Hack, Sameh A. Abdelnour, Kuldeep Dhama, Ayman A. Swelum, and Alessandro Di Cerbo. "Dandelion Herb: Chemical Composition and Use in Poultry Nutrition." In Antibiotic Alternatives in Poultry and Fish Feed, 124–36. BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/9789815049015122010012.

Full text

Abstract:

Taraxacum officinale, also known as dandelion herb, is a popular medicinal and therapeutic herb used for many years and is mostly raised in Europe, Asia, North and South America. It contains several nutrients and bioactive substances, especially the leaves and roots of this herb, which are a rich source of fiber, lecithin, choline, and micronutrients such as minerals (potassium, magnesium, calcium, zinc, etc., iron) and vitamins (A, C, K, and B-complex). The root has been commonly used for digestive and liver problems due to its stimulatory effects on the production of bile and detoxification functions. The leaves of dandelion have stimulatory functions on the digestive system and possess diuretic effects. Furthermore, several studies have shown that dandelion leaves can enhance the growth and productivity of poultry. Various functions on the intestinal mucosa have been reported, including the effects on the architecture of villi, villus height/crypt depth ratio, and cellular infiltration. This herb also has various beneficial functions, such as immunomodulatory effects, stimulation of the digestive system and insulin activation, enhancing the metabolism of androgens, and acting as a probiotic, antiangiogenic, antineoplastic and demulcent. Moreover, the dandelion herb can treat indigestions and hepatitis B infection. Due to the lack of studies on the effects of dandelion, further research has to be conducted to exploit the medicinal properties of this herb for its beneficial health impact on humans, pet and livestock animals (e.g., poultry) nutrition.

APA, Harvard, Vancouver, ISO, and other styles

6

Boumaiza, Mohamed, Samia Rourou, Paolo Arosio, and Mohamed Nejib Marzouki. "The Use of Ferritin as a Carrier of Peptides and Its Application for Hepcidin." In BioMechanics and Functional Tissue Engineering [Working Title]. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.94408.

Full text

Abstract:

Hepcidin a 25-amino-acid and highly disulfide bonded hormone, is the central regulator of iron homeostasis. In this chapter we propose ferritin as a peptide carrier to promote the association of the hybrid hepcidin/ferritin nanoparticle with a particular cell or tissue for therapeutic or diagnostic use. Indeed, human ferritin H-chain fused directly (on its 5’end) with camel mature hepcidin was cloned into the pASK-43 plus vector and expressed using BL21 (DE3) pLys E. coli strain. The transformed E.coli produced efficiently hepcidin-ferritin construct (hepcH), consisting of 213 amino acids with a molecular weight of 24 KDa. The recovered product is a ferritin exposing hepcidin on outer surface. The hepcH monomer was characterized by immunoblotting using a monoclonal antibody specific for human ferritin and a polyclonal antibody specific for hepcidin-25. The results were also confirmed by MALDI-TOF mass spectrometry. The recombinant native human ferritin and the commercial human hepcidin-25 were used as controls in this experiment. The assembly of hepcH, as an heteropolymer molecule, was performed in presence of denatured human ferritin-H and -L chains. After cysteine oxidation of the recombinant nanoparticles, cellular binding assays were performed on mammalian cells such as mouse monocyte–macrophage cell line J774, HepG2 and COS7.

APA, Harvard, Vancouver, ISO, and other styles

7

Singh, Indu, Janelle Guerrero, and Michael J. Simmonds. "Developing a National Registry for Hemochromatosis." In Improving Health Management through Clinical Decision Support Systems, 154–64. IGI Global, 2016. http://dx.doi.org/10.4018/978-1-4666-9432-3.ch007.

Full text

Abstract:

Hereditary Hemochromatosis (HH) is a disorder where iron and ferritin concentrations in a patient's blood are much higher than normal healthy levels. The main therapeutic intervention for individuals with HH is removing 300-500 mL of blood every few months to maintain ferritin concentration within acceptable ranges. The blood collected during these venesections is usually discarded as there is a belief that blood with high levels of ferritin are not suitable for blood transfusion purposes. Australian Red Cross Blood Services voluntarily collects blood from donors for subsequent use in blood transfusion. Annually more than 700 thousand units are transfused within Australia and there is a constant need for new donors given the significant imbalance between supply and demand of blood products. Besides red cell transfusions, the Red Cross also issues donor blood for development of many other blood products essential for patient health care. The HH blood can currently be used for other blood products if not for red cell transfusion. However, there is evidence to suggest that there is no significant difference between the red cells of the normal healthy population compared to those from HH patients. Australian Red Cross has developed a mobile computer application (High Ferritin “app”) as they have started collecting blood from HH patients. Though there is little or no awareness about the existence and use of this High Ferritin app in general HH population, their doctors and nurses collecting their blood for therapeutic purposes. This chapter describes possibility of saving and utilizing the blood collected from hemochromatosis patients for therapeutic purposes. A national hemochromatosis patients registry, in collaboration with High Ferritin app (HFa) developed by Australian Red Cross Blood Services, accessible to the patients, their doctors and Red Cross Blood Collection Sservices 24 hours a day anywhere in the country can allow the patients to donate the blood collected for therapeutic purposes at any affiliated blood collection center in the country after they automatically get a message either by email or text message after their blood results have been reviewed by their doctor and they are required to go for venesection.

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Iron Therapeutic use Tanzania"

1

Ristic, Bojana, Sathish Sivaprakasam, Jiro Ogura, and Vadivel Ganapathy. "Abstract 4477: Downregulation of ABCG2 expression in colitis and colon cancer: Relevance to iron overload, hemochromatosis and p53, and therapeutic use of carbidopa to reverse the downregulation." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4477.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Yuan, Yuan, and Diana-Andra Borca-Tasciuc. "The Influence of Coating and Agglomeration on Specific Absorption Rate of Iron Oxide Nanoparticles." In ASME 2011 9th International Conference on Nanochannels, Microchannels, and Minichannels. ASMEDC, 2011. http://dx.doi.org/10.1115/icnmm2011-58217.

Full text

Abstract:

Magnetic nanofluids can be remotely heated by alternating magnetic field and have significant potential for cancer hyperthermia therapy. The heat generated by magnetic nanoparticles is typically quantified by the specific absorption rate (SAR), which represents the thermal power per unit mass of magnetic material generated in the presence of an alternating magnetic field. During hyperthermia treatment, heat dosage of tumor tissue correlates with slowing tumor growth. The therapeutic ratios of cancer can be increased with the use of biofunctionalized magnetic nanoparticles that have higher SAR for modest amplitudes of magnetic field[1]. Hence, understanding the factors that control the heat generation of magnetic nanoparticle suspensions is important to design fluids with optimized biocompatibility and functionality. In all biomedical applications, the nanoparticles must be coated on the surface to prevent their agglomeration [2], enhance biocompatibility and allow targeting to a specific area. Existing studies have shown that the SAR of nanoparticles may change in the presence of functional coating[3–5]. However, while these studies show that the coating may affect the heat generation rate, there is a limited understanding on the mechanisms that cause that changes of SAR. Hence, it is important to carry out a systematic investigation of nanoparticles similar in size but with different organic coating relevant to biomedical applications to obtain a more complete picture of the mechanisms contributing to changes in SAR. In this work, we present a review of our efforts in this area. Specifically, in our studies we are investigating the correlation between the magnetic and physical properties of commercially available nanoparticles systems and their heat generation rate. The susceptibility and SAR of suspensions of coated and uncoated iron oxide nanoparticles of similar particle size are measured. The coatings selected are highly relevant to biomedical applications and include amine and carboxyl functionalization as well as bioaffine ligands such as protein and biotin. The particle and cluster size was determined from transmission electron microscope (TEM), X-Ray diffraction (XRD) and Dynamic light scattering (DLS). TEM and DLS studies suggested that clusters exist in samples. A summary of all morphological properties together with pH of each suspension is shown in Table.1. The AC magnetic susceptibility of the suspensions was measured as a function of frequency with an in-house made apparatus. Finally SAR was determined by heating the suspension in a commercial induction system and measuring the temperature rise as function of time with a fiber optic sensor. Following these measurements, the SAR values were predicted in two ways: 1) based on measured AC susceptibility and 2) based on particle physical and magnetic properties, starting from Debye model for susceptibility. The normalized predicted and experimental SAR values for all samples are also shown in Table 1. From Table 1, it was found that pH may influence aggregation as described in Ref [6], which indicated that at pH about 2 nanoparticles are highly charged preventing their aggregation while in pH in 6–10 suspensions aggregations are more significant. Normalized SAR of nanoparticle system with aggregations seems to be not related to concentration, different from the well dispersed system[7]. The carboxyl coated sample has smallest diameter and show the lowest SAR, as reported in Ref[8]. The results of suspensions of uncoated iron oxide nanoparticles as well as particles coated with amine groups show that normalized experimental SAR (NSARE) agrees relatively well with calculated SAR using experimental susceptibility (NSARC_χ″E); poor agreement was found when experimental susceptibility was substituted with calculated one (NSART_χ″C) using Debye model, which is developed for non-interacting magnetic particles. These results suggest that the coating do not have a direct effect on SAR. On the other hand, agglomeration, which was present in both samples, may lead to dipolar interaction between nanoparticles and enhancement in magnetic properties and SAR. For carboxyl coated sample which has negligible clustering, showed no temperature increase and zero imaginary part of susceptibility. Therefore, good agreement between Debye-model based predictions of SAR and experimental results were obtained in this sample. However, unexpected results were obtained for bioaffine ligands coated sample, where the experimental SAR values are higher than the SAR values determined based on experimental susceptibility. Protein coated sample, which has the larger clusters among the two samples, has a heat generation rate is 6 times higher than the prediction. Meanwhile, the biotin coated sample which has relatively smaller clusters show only a small increase in heat generation rate. A possible explanation for these results is the loss of superparamagnetic character and an opening in hysteresis loop at test frequency for suspensions with large clusters, which may increase the dissipated power above that produced by the relaxation heat losses [9]. Above results show that coating had little effect on SAR. On the other hand, aggregations and clusters may significantly affect SAR, possibly due to dipolar interaction between nanoparticles in suspensions with relatively small clusters or loss of superparmagnetic characters when very large clusters are present.

APA, Harvard, Vancouver, ISO, and other styles

3

Al-Ansari, Dana E., Nura A. Mohamed, Isra Marei, Huseyin Yalcin, and Haissam Abou-Saleh. "Assessment of Metal Organic Framework as Potential Drug Carriers in Cardiovascular Diseases." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0127.

Full text

Abstract:

Background: Cardiovascular diseases (CVDs) are considered the major cause of death worldwide. Therapeutic delivery to the cardiovascular system may play an important role in the successful treatment of a variety of CVDs, including atherosclerosis, ischemic-reperfusion injury, and microvascular diseases. Despite their clinical benefits, current therapeutic drugs are hindered by their short half-life and systemic side effects. This limitation could be overcome using controlled drug release with the potential for targeted drug delivery using a nanomedicine approach. In the current study, we have assessed the use of a highly porous nano-sized preparation of iron-based Metal-organic Framework (MOF) commonly referred to as MIL-89 as potential drug carriers in the cardiovascular system. Aims: To assess the effect of MOFs on the viability and cytotoxicity of human vascular cells and the cellular uptake in vitro, and the organ-system toxicity of MOF in vivo using the Zebrafish model. Methods: Human pulmonary endothelial cells (HPAECs) and pulmonary smooth muscle cells (HPASMCs) were treated with variable concentrations of MOFs. The viability, cytotoxicity and anti-inflammatory effects were measured using AlamarBlue, LDH assay and ELISA. The cellular uptake of MOFs were assessed using light, confocal, and transmission electron microscopes and EDS analysis. Moreover, Zebrafish embryos were cultured and treated with MOFs-nanoparticles at 0 hours post fertilization (hpf) followed by different organ-specific assays at 24, 48, and 72 hpf. Results: Although MOFs affect the viability at high concentrations, it does not cause any significant cytotoxicity on HPAECs and HPASMCs. Interestingly, MOFs were shown to have an anti-inflammatory effect. Microscopic images showed an increased (concentration-dependent) cellular uptake of MOFs and transfer to daughter cells in both cell types. Moreover, the in vivo study showed that high concentrations of MOFs delay zebrafish embryos hatching and cause heart deformation, which is currently investigated using cardiotoxicity markers. Conclusion: MOFs is a promising nanoparticle prototypes for drug delivery in the cardiovascular system with high cellular uptake and anti-inflammatory effects. Further investigations of MOFs, including diseased models and drug- loaded formulation is required.

APA, Harvard, Vancouver, ISO, and other styles

4

Babarykin, Dmitry, Gaļina Smirnova, Svetlana Vasiļjeva, Anna Fedotova, Andrey Fedotov, and Natālija Basova. "Evaluation of the biological activity of sugar-free fractionated red beetroot juice." In 80th International Scientific Conference of the University of Latvia. University of Latvia, 2023. http://dx.doi.org/10.22364/iarb.2022.05.

Full text

Abstract:

In the case of type II diabetes, the most important preventive and therapeutic effect gives a diet with a minimal amount of easily digestible carbohydrates. Vegetable juices are posi-tioned as healthy food, because of the high content of phenolic and other biologically active compounds. However, due to the high glycemic index, juices are contraindicated in obesity, and diabetes, while juices with a reduced glycemic index, are not available on the market. We have developed a technology for the fractionation of red beetroot juice based on molecular mass using ultrafiltration. The resulting fraction stimulates the absorption of iron, increases blood hemoglobin level, and enhances capillary blood flow more effectively than native juice does. Both effects are important for patients with diabetes because the impaired blood supply to tissues and organs is an important pathogenetic factor in the development of diabetic renal failure, blindness, and gangrene. The sugar content in fractionated beetroot juice is 5–7%, which makes its use in diabetes problematic. The purpose of the study was to develop a technology for removing sugar from fractionated red beetroot juice and assessing the safety of its functional properties. The fractionated native red beetroot juice and fractionated fermented juice were studied. Fermentation was carried out using pre-activated yeast Saccharomyces cerevisiae. It was found that after 5-day fermentation, the sugar content in the fermented fractionated juice fell to 0.5–0.7%, while maintaining functional activity.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!